Photochemotherapeutical obstruction of newly-formed blood vessels

a technology of newly formed blood vessels and photochemotherapeutics, which is applied in the direction of biocide, heterocyclic compound active ingredients, drug compositions, etc., can solve the problems of severe visual loss, serious visual disturbance, and much slowly metabolized in vivo

Inactive Publication Date: 2001-05-15
MEIJI SEIKA KAISHA LTD
View PDF6 Cites 29 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

.Iadd.photosensitive .Iaddend.substance of the first generation are accompanied by their drawback that they are very much slowly metabolized in vivo.
Neovascularization of any ocular tissue causes serious visual disturbance.
In age-related macular degeneration, choroidal neovascularization causes subretinal hemorrhage, exudates and fibrosis, leading to severe visual loss.
Laser photocoagulation has heretofore been used for the therapeutic treatment of choroidal (ocular) neovascularization but is not a perfect method, because it damages overlying sensory retina by propagating heat.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Photochemotherapeutical obstruction of newly-formed blood vessels
  • Photochemotherapeutical obstruction of newly-formed blood vessels
  • Photochemotherapeutical obstruction of newly-formed blood vessels

Examples

Experimental program
Comparison scheme
Effect test

example 1

OF FORMULATION

The following ingredients were mixed together in the proportions by weight as indicated below, to prepare a basal powder:

Sucrose 80.3 grams Tapioca starch 13.2 grams Magnesium stearate 4.4 grams

The basal powder so obtained was mixed well with an appropriate amount of .[.NPe6.]. .Iadd.mono-L-aspartyl chlorin e6 tetra-sodium salt .Iaddend.and the resulting mixture was shaped into tablets by a conventional tableting method, so that there were produced tablets each containing 100 mg of .[.NPe6.]. .Iadd.mono-L-aspartyl chlorin e6 tetra-sodium salt .Iaddend.as the active ingredient.

example 2

OF FORMULATION

In a volume of physiological saline were dissolved 200 mg of .[.NPe6.]. .Iadd.mono-L-aspartyl chlorin e6 tetra-sodium salt .Iaddend.to give an aqueous solution which contained .[.NPe6.]. .Iadd.mono-L-aspartyl chlorin e6 tetra-sodium salt .Iaddend.dissolved in the saline at a final .[.NPe6.]. .Iadd.mono-L-aspartyl chlorin e6 tetra-sodium salt .Iaddend.concentration of 20 mg per ml. The resulting solution was sterilized in a conventional manner to afford an injectable solution of .[.NPe6.]. .Iadd.mono-L-aspartyl chlorin e6 tetra-sodium salt.Iaddend., which is suitable for intravenous administration and also for intramuscular administration for the photochemotherapeutic purposes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
timeaaaaaaaaaa
poweraaaaaaaaaa
Login to view more

Abstract

A photosensitive tetrapyrrole derivative having formula (I)where n stands for 1 or 2 or a pharmaceutically acceptable salt thereof is useful as an effective ingredient in an obstruent composition for photochemotherapeutically obstructing neovascular vessels. The photosensitive tetrapyrroles of the formula (I) may be administered in a photochemotherapeutic method for obstructing neovascular vessels, particularly choroidal and retinal neovascularizations.

Description

FIELD OF THE INVENTIONThe present invention relates to an obstruent composition for use in photochemotherapeutical obstruction or occlusion of newly-formed or neovascular blood vessels as formed in a patient. The present invention also relates to a method for photochemotherapeutically obstructing neovascular vessels as formed in a patient having the neovascular vessels in eyes, cutaneous tissue or visceral tissue.BACKGROUND OF THE INVENTIONThe photochemotherapeutical method means such a chemotherapeutical method which makes use of a photosensitive substance capable of displaying a therapeutic action or medical action for the first time only when said substance is elicited photochemically by being irradiated with light, for example, ultraviolet rays or a beam of laser light, and in which, after the administration of said photosensitive substance, either such part or parts of the tissues of a living body of the patient where the photosensitive substance as administered has been presen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K41/00A61K31/409C07D487/22A61K31/00A61K31/40A61P27/00A61P27/02A61P27/04A61P43/00
CPCA61K31/409A61K41/0071A61P27/00A61P27/02A61P27/04A61P43/00
Inventor MORI, KEISUKEOHTA, MASATAKAMORI, SHIGERUYONEYA, SHINHAYASHI, NAOKISONODA, MASARU
Owner MEIJI SEIKA KAISHA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap